Correspondence

References

• Jacob KS. The use of multiple psychotropic medication in the treatment of mental disorders. Australian and New Zealand Journal of Psychiatry 1995; 29: 186–188
   PubMed Web of Science ®Google Scholar
• Lam TP. Why should we prevent polypharmacy?. The Hong Kong Practitioners 1995; 17: 345–346
   Google Scholar
• Good BJ. Culture, diagnosis and comorbidity. Culture, Medicine and Psychiatry 1993; 16: 427–446
   Web of Science ®Google Scholar
• Kirmayer LJ. The place of culture in psychiatric nosology: Taijin kyofusho and DSM-HI-R. Journal of Nervous and Mental Disease 1991; 179: 19–28
   PubMed Web of Science ®Google Scholar
• Bergen J. Brief comment on: Jacob KS. The use of multiple psychotropic drugs in the treatment of mental disorders. Australian and New Zealand Journal of Psychiatry 1995; 29: 189
   Google Scholar
• Clark AF, Holden NL. The persistence of prescribing patterns: a survey and follow up of prescribing to chronic hospital patients. British Journal of Psychiatry 1987; 150: 88–91
   PubMed Web of Science ®Google Scholar
• Anderson DN. A comparison of inpatient and outpatient prescribing. British Journal of Psychiatry 1989; 154: 644–649
   PubMed Web of Science ®Google Scholar
• Morgan R, Gopalaswamy AK. Psychotropic drugs: another survey of prescribing patterns. British Journal of Psychiatry 1984; 144: 298–302
   PubMed Web of Science ®Google Scholar
• Goodwin FK. Psychiatry. Journal of the American Medical Association 1994; 271: 1707–1708
   Google Scholar
• Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics 1993; 92: 39–43
   PubMed Web of Science ®Google Scholar
• Swedo S, Leonard H, Kiessling M. Speculations on anti-neuronal antibody mediated neuropsychiatric disorders of childhood. Pediatrics 1994; 93: 323–326
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL, Schapiro MB, Casey BJ, Mannheim GB, Lenane MC, Rettew DC. Sydenham‘s chorea: physical and psychological symptoms of St Vitus’ dance. Pediatrics 1993; 91: 706–713
   PubMed Web of Science ®Google Scholar
• Cavallo MG, Baroni MG, Toto A, Gearing AJ, Forsey T, Andreani D, Thorpe R, Pozzilli P. Viral infection induces cytokine release by beta islet cells. Immunology 1992; 75: 664–668
   PubMed Web of Science ®Google Scholar
• Pearce BD, Hobbs MV, McGraw TS, Buchmeier MJ. Cytokine induction during Tcell-mediated clearance of mouse hepatitis virus from neurons in vivo. Journal of Virology 1994; 68: 5483–5495
   PubMed Web of Science ®Google Scholar
• Byerley LO, Alcock NW, Starnes HF, Jr. Sepsis-induced cascade of cytokine mRNA expression: correlation with metabolic changes. American Journal of Physiology 1992; 262: E728–735
   Google Scholar
• Vara E, Arias-Diaz J, Garcia C, Balibrea JL. Cytokine-induced inhibition of lipid synthesis and hormone secretion by isolated human islets. Pancreas 1994; 9: 316–323
   PubMedGoogle Scholar
• Ciampolillo A, Guastamacchia E, Caragiulo L, Lollino G, De-Robertis O, Lattanzi V, Giorgino R. In vitro secretion of inter-leukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients. Diabetes Research and Clinical Practice 1993; 21: 87–93
   PubMedGoogle Scholar
• Suarez-Pinzon WL, Strynadka K, Schulz R, Rabinovitch A. Mechanisms of cytokine-induced destruction of rat insulinoma cells: the role of nitric oxide. Endocrinology 1994; 134: 1006–1010
   PubMedGoogle Scholar
• Jobe LW, Vertrees S, Wilson CA, Jacobs C. Wilson DL, Picha KS, Baker P, Lernmark A. In vivo effects of interleukin-1 beta on blood leukocytes in BB rats prone or resistant to diabetes. Autoimmunity 1992; 11: 233–237
   Google Scholar
• Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophrenia Research 1994; 12: 29–34
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 1994; 89: 346–351
   PubMed Web of Science ®Google Scholar
• Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research 1994; 51: 1–10
   PubMed Web of Science ®Google Scholar
• Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, Kinoshita N, Yagi G. Serum interleukin-6 in schizophrenic patients. Life Science 1991; 49: 661–664
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry 1993; 150: 1792–1798
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS. Functional imaging of the brain in psychiatry: positron emission tomography and blood flow studies. American handbook of psychiatry. Vol 8. New York: Basic Books, PA Berger, KH Brodie, 1986; 236–248
   Google Scholar
• Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, Hellerstrom C. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. Journal of Clinical Investigation 1994; 93: 1968–1974
   PubMed Web of Science ®Google Scholar
• Jhala U, Baly DL. Effect of chronic IL-1 beta infusion on glucose homeostasis and pancreatic insulin secretion. Life Sciences 1994; 54: 413–422
   PubMedGoogle Scholar
• Ohno Y, Aoki N, Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1993; 77: 1072–1077
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271–1278
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor alpha. Journal of Clinical Investigation 1994; 94: 1543–1549
   Google Scholar
• Brekke OL, Espevik T, Bardal T, Bjerve KS. Effects of n-3 and n-6 fatty acids on tumor necrosis factor cytotoxicity in WEHI fibrosarcoma cells. Lipids 1992; 27: 161–168
   PubMedGoogle Scholar
• Borkman M, Storlein LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. New England Journal of Medicine 1993; 328: 238–244
   PubMed Web of Science ®Google Scholar
• Storlein LH, Borkman M, Jenkins AB, Campbell LV. Diet and in vivo insulin action: of rats and man. Diabetes, Nutrition and Metabolism 1991; 4: 227–240
   Google Scholar
• Mauduit C, Jaspar JM, Poncelet E, Charlet C, Revol A, Franchimont P, Benahmed M. Tumor necrosis factor-alpha antagonizes follicle-stimulating hormone action in cultured Sertoli cells. Endocrinology 1993; 133: 69–76
   PubMed Web of Science ®Google Scholar
• Best CL, Pudney J, Anderson DJ, Hill JA. Modulation of human granulosa cell steroid production in vitro by tumor necrosis factor alpha: implications of white blood cells in culture. Obstetrics and Gynaecology 1994; 84: 121–127
   Google Scholar
• Horrobin DF, Manku MS, Hillman H, Glen AI, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 1991; 30: 795–805
   PubMed Web of Science ®Google Scholar
• Horrobin DF. The relationship between schizophrenia and essential fatty acid and eicosanoid metabolism. Prostaglandins, Leukotrienes and Essential Fatty Acids 1992; 46: 71–77
   PubMedGoogle Scholar
• Iacono WG, Beiser M. Are males more likely than females to develop schizophrenia?. American Journal of Psychiatry 1992; 149: 1070–1074
   PubMed Web of Science ®Google Scholar
• Pearlson G, Pulver AE. Sex, schizophrenia and the cerebral cortex. Schizophrenia: exploring the spectrum of psychosis. New York: Wiley, RJ Ancill, S Holliday, J Higenbottam, 1994; 345–362
   Google Scholar
• Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biological Psychiatry 1993; 33: 207–209
   PubMed Web of Science ®Google Scholar
• Checkley SA, Wieck A, Marks M, Kumar R, Beam JA, Campbell I. Neuroendocrine studies of aetiology of puerperal psychosis. Clinical Neuropharmacology 1992; 15: 212A–213A
   Google Scholar
• Seeman MV, Lang M. The role of oestrogens in schizophrenia gender differences. Schizophrenia Bulletin 1990; 16: 185–194
   PubMed Web of Science ®Google Scholar
• De M, Sanford TR, Wood GW. Interleukin-1, interleukin-6, and tumor necrosis factor alpha are produced in the mouse uterus during the oestrous cycle and are induced by oestrogen and progesterone. Developmental Biology 1992; 151: 297–305
   PubMed Web of Science ®Google Scholar
• Kaplan R. Correspondence. False memory syndrome. Australian and New Zealand Journal of Psychiatry 1995; 29: 516–517
   PubMedGoogle Scholar
• Taylor AT. Catatonia: a review of a behavioural neurological syndrome. Neuropsychiatry, Neuropsychology and Behavioural Neurology 1990; 3: 48
   Google Scholar
• Gelenberg AJ, Mandel MR. Catatonic reaction to high-potency neuroleptic drugs. Archives of General Psychiatry 1977; 34: 947–950
   PubMed Web of Science ®Google Scholar
• Fink M. Is catatonia a primary indication for ECT?. Convulsive Therapy 1990; 6: 1–4
   PubMedGoogle Scholar
• Fricchione G. Catatonia: a new indication for benzodiazepine. Biological Psychiatry 1989; 26: 761–765
   PubMedGoogle Scholar
• Rosebush PI, Hildebrand AM, Furlong BG. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. Journal of Clinical Psychiatry 1990; 51: 357–362
   PubMed Web of Science ®Google Scholar
• Yassa R, Iskandar H, Lalines M, Cleto L. Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial. Journal of Clinical Psychopharmacology. 1990, 10;66-68
   Google Scholar
• Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatrica Scandinavica 1994; 89: 28–288
   Google Scholar
• Lee WYJ. Catatonia: the tension insanity. British Journal of Psychiatry 1993; 163:696. Published erratum appears in British Journal of Psychiatry 1994; 164: 1341
   Google Scholar
• Salam SA, Pillai AK, Beresford TP. Lorazepam for psychogenic catatonia. American Journal of Psychiatry 1987; 144: 1082–1083
   PubMed Web of Science ®Google Scholar